At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Rituximab, Bendamustine, Mitoxantrone, Dexamethasonedrug
Likely dose
Rituximab, Bendamustine, Mitoxantrone, Dexamethasone 90 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients With Follicular Lymphoma Refractory or Relapsed
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea·interventional·Posted May 28, 2010·Updated Nov 1, 2018
In Brief
A Phase 2 clinical trial evaluating Rituximab, Bendamustine, Mitoxantrone, Dexamethasone for Non-Hodgkin's Lymphoma. Completed, enrolled 61 participants across 41 sites.
Detailed Summary
Assess the combination of efficacy of the combination of rituximab, bendamustine, mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma
CountriesSpain
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedMay 2010
Primary CompletionDec 2013
Study CompletionJul 2016
TodayJul 2026
First PostedMay 28, 2010
Enrollment StartJul 1, 2009
Primary CompletionDec 1, 2013
Study CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 16.1 years ago
Interventions
Rituximab, Bendamustine, Mitoxantrone, Dexamethasonedrug
Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv